Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Horowitz, Amir"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-5 z 5
    Tytuł:
    A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment.
    Autorzy:
    Wei CH; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Huang L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kreh B; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Liu X; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Tyutyunyk-Massey L; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Kawakami M; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Chen Z; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Shi M; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Kozlov S; Center for Advanced Preclinical Research, Frederick, MD, USA.
    Chan KC; Protein Characterization Laboratory, Frederick, MD, USA.
    Andresson T; Protein Characterization Laboratory, Frederick, MD, USA.
    Carrington M; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
    Vuligonda V; Io Therapeutics, Inc., Spring, TX, USA.
    Sanders ME; Io Therapeutics, Inc., Spring, TX, USA.
    Horowitz A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Moffitt Cancer Center, Tampa, FL, USA.
    Peng W; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Dmitrovsky E; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA.
    Liu X; Molecular Pharmacology Program, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, 21701, USA. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2023 Sep 09; Vol. 13 (1), pp. 14907. Date of Electronic Publication: 2023 Sep 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
    MeSH Terms:
    CD8-Positive T-Lymphocytes*
    Lung Neoplasms*/drug therapy
    Animals ; Mice ; Interleukin-13 ; Interleukin-5 ; Tumor Microenvironment ; Receptors, Retinoic Acid ; Tretinoin ; Carcinogenesis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.
    Autorzy:
    Bernson E; Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hosptial, Cambridge CB2 0QQ, UK.; Sahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
    Huhn O; Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hosptial, Cambridge CB2 0QQ, UK.
    Karlsson V; Sahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
    Hawkes D; Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hosptial, Cambridge CB2 0QQ, UK.
    Lycke M; Sahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
    Cazzetta V; Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.; Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20122 Milan, Italy.
    Mikulak J; Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
    Hall J; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 1TN, UK.
    Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 1TN, UK.
    Portuesi R; Unit of Gynecology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
    Vitobello D; Unit of Gynecology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
    Fiamengo B; Unit of Pathological Anatomy, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
    Siesto G; Unit of Gynecology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
    Horowitz A; Department of Oncological Sciences, Lipschultz Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
    Ghadially H; AstraZeneca, Oncology R&D, Granta Park, Cambridge CB21 6GP, UK.; Department of Pathology, School of Medicine and Oral Health, Kamuzu University of Health Sciences, Mahatma Gandhi Road, Blantyre Private Bag 360, Malawi.
    Mavilio D; Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.; Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20122 Milan, Italy.
    Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 1TN, UK.
    Sundfeldt K; Sahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
    Colucci F; Department of Obstetrics and Gynaecology, University of Cambridge School of Clinical Medicine, NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hosptial, Cambridge CB2 0QQ, UK.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Jun 27; Vol. 15 (13). Date of Electronic Publication: 2023 Jun 27.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    MiDAS-Meaningful Immunogenetic Data at Scale.
    Autorzy:
    Migdal M; Roche Global IT Solution Centre (RGITSC), Warsaw, Poland.
    Ruan DF; Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
    Forrest WF; Department of OMNI Bioinformatics, Genentech, South San Francisco, California, United States of America.
    Horowitz A; Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
    Hammer C; Department of Cancer Immunology, Genentech, South San Francisco, California, United States of America.; Department of Human Genetics, Genentech, South San Francisco, California, United States of America.
    Pokaż więcej
    Źródło:
    PLoS computational biology [PLoS Comput Biol] 2021 Jul 06; Vol. 17 (7), pp. e1009131. Date of Electronic Publication: 2021 Jul 06 (Print Publication: 2021).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Databases, Genetic*
    Software*
    Computational Biology/*methods
    Immunogenetic Phenomena/*genetics
    Evolution, Molecular ; HLA Antigens/genetics ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.
    Autorzy:
    Ramsuran V; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
    Naranbhai V; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
    Horowitz A; Department of Oncological Sciences, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
    Qi Y; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Martin MP; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Yuki Y; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Gao X; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Walker-Sperling V; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
    Del Prete GQ; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Schneider DK; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Lifson JD; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
    Fellay J; School of Life Sciences, École Polytechnique Fédérale de Lausanne, and Swiss Institute of Bioinformatics, Lausanne, Switzerland.
    Deeks SG; Department of Medicine University of California, San Francisco, CA 94143, USA.
    Martin JN; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143, USA.
    Goedert JJ; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.
    Wolinsky SM; Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
    Michael NL; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
    Kirk GD; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.
    Buchbinder S; Department of Medicine University of California, San Francisco, CA 94143, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143, USA.; San Francisco Department of Public Health, HIV Research Section, San Francisco, CA 94102, USA.
    Haas D; Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
    Ndung'u T; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.; African Health Research Institute, Durban, South Africa.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.; Max Planck Institute for Infection Biology, Berlin, Germany.
    Goulder P; African Health Research Institute, Durban, South Africa.; Department of Paediatrics, University of Oxford, Oxford, UK.
    Parham P; Departments of Structural Biology and Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
    Walker BD; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.; African Health Research Institute, Durban, South Africa.; Institute for Medical and Engineering Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
    Carlson JM; Microsoft Research, Redmond, WA 98052, USA.
    Carrington M; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. .; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2018 Jan 05; Vol. 359 (6371), pp. 86-90. Date of Electronic Publication: 2018 Jan 04.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    HIV/*immunology
    HIV Infections/*immunology
    HLA Antigens/*metabolism
    Killer Cells, Natural/*immunology
    NK Cell Lectin-Like Receptor Subfamily C/*metabolism
    Alleles ; CD4 Lymphocyte Count ; Cohort Studies ; HIV Infections/drug therapy ; HIV Infections/genetics ; HLA Antigens/genetics ; Humans ; Ligands ; NK Cell Lectin-Like Receptor Subfamily C/antagonists & inhibitors ; NK Cell Lectin-Like Receptor Subfamily C/genetics ; Protein Sorting Signals ; Viremia/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report.
    Autorzy:
    Markowitz M; Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA. />Mohri H
    Mehandru S
    Shet A
    Berry L
    Kalyanaraman R
    Kim A
    Chung C
    Jean-Pierre P
    Horowitz A
    La Mar M
    Wrin T
    Parkin N
    Poles M
    Petropoulos C
    Mullen M
    Boden D
    Ho DD
    Pokaż więcej
    Źródło:
    Lancet (London, England) [Lancet] 2005 Mar 19-25; Vol. 365 (9464), pp. 1031-8.
    Typ publikacji:
    Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Drug Resistance, Multiple, Viral*
    HIV-1*/chemistry
    HIV-1*/drug effects
    HIV-1*/genetics
    HIV-1*/physiology
    Acquired Immunodeficiency Syndrome/*virology
    HIV Infections/*virology
    Acquired Immunodeficiency Syndrome/drug therapy ; Adult ; CD4 Lymphocyte Count ; Disease Progression ; HIV Infections/drug therapy ; HIV Infections/immunology ; Humans ; Male ; Receptors, CCR5/analysis ; Receptors, CXCR4/analysis ; T-Lymphocyte Subsets ; Virus Replication
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-5 z 5

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies